Post by
throwaway11 on Aug 25, 2024 6:43pm
Questions
Going to plead ignorance on the subject of biological agents but have some questions which I suppose some long investors here are able to answer.
How does bee vectoring's agent compare with other already established biological agents that prevent or act against unwanted plant pathogens? There are many already on the market. Is there a comparison chart somewhere showing it against the most widely available brands?
Secondly does economy of scale, integration of new companies (via Acq etc), etc work in favor of Bee Vectoring? If so, is labor still cost big for either BeeV or their customers in order to practically use their equipment?
Thirdly if the CEO is paying himself $300k+ per year when the company is losing money after years of being public, WHY should anybody buy shares? IMO when you see that kind of thing, any further financing will probably come at the guarantee to the financing party that they're able to dump a lot of paper on shareholders.
Comment by
stockwatcher7 on Aug 26, 2024 10:57am
This post has been removed in accordance with Community Policy
Comment by
throwaway11 on Aug 29, 2024 1:31pm
With respect, I am not asking for an NR from the company advocating for itself. There are already fungi-based anti-pathogenic agents on the market (as well as others similar, like mycological ones) and have been for years. Has Bee Vectoring actually directly compared themselves to them?
Comment by
stockwatcher7 on Sep 03, 2024 8:48pm
This post has been removed in accordance with Community Policy
Comment by
singlefile on Sep 15, 2024 9:01am
Crickets ..... which I believe BEE has a solution for - just get the stock price to 10 cents + ... poof crickets"b"gone